News | Heart Failure | April 21, 2023

Study Finds Equitable Heart Failure Care, but Challenges Remain

A new study finds hospitals in the American Heart Association’s Get With The Guidelines - Heart Failure program exhibit no disparities in heart failure care between Black and white patients

A new study finds hospitals in the American Heart Association’s Get With The Guidelines - Heart Failure program exhibit no disparities in heart failure care between Black and white patients

Human Chest Cavity illustration: Right lung, left lung, heart. Copyright American Heart Association 


April 21, 2023 — Black adults with heart failure (HF) are more likely to die than white adults with the same condition.[1] A new study published today in JAMA Cardiology that used the American Heart Association’s Get With The Guidelines - Heart Failure registry data to examine quality and outcomes at hospitals treating high proportions of Black patients with HF found that care is equitable, although areas for improvement remain to examine quality and outcomes at hospitals treating high proportions of Black patients with HF found that care is equitable, although areas for improvement remain. 

For the study, researchers used a comprehensive set of quality measures to examine data on clinical treatment decisions and health outcomes from nearly 500 hospitals fully participating in Get With The Guidelines - HF, an in-hospital program for improving care by promoting consistent adherence to the latest scientific treatment guidelines. They found that quality of heart failure care was equitable for 11 of 14 evidence-based clinical care measures and that there were no in-hospital disparities in care between Black and white patients. 

“These findings suggest Get With The Guidelines can help hospitals achieve equitable care for patients hospitalized with heart failure, an important American Heart Association aim,” said Gregg Fonarow, M.D., FAHA, an author of the study and an American Heart Association volunteer.  Fonarow is interim chief of the division of cardiology, director of the Ahmanson-UCLA Cardiomyopathy Center, co-director of the Preventative Cardiology Program and the Eliot Corday Chair in Cardiovascular Medicine and Science at the University of California, Los Angeles. “While there remain critical population-level disparities in access to care, social determinants of health and care quality in other settings, the Get With The Guidelines - HF program is having an important impact.” 

The study suggests inequities in HF outcomes are not only driven by gaps in care quality at hospitals, but also that there is a need for renewed focus on public health and policy efforts to target upstream factors that disproportionately affect Black adults. Researchers note that the findings have important implications for public policymakers, health system leaders and clinicians as they work toward equitable delivery of HF care. 

“For more than 20 years, Get With The Guidelines has made strides toward equitable, evidence-based care for all,” said Michelle Albert, MD, MPH, FACC, FAHA, volunteer president of the American Heart Association and the Walter A. Haas-Lucie Stern Endowed chair in cardiology and professor in medicine at the University of California at San Francisco (UCSF), admissions dean for UCSF Medical School and director of the CeNter for the Study of AdveRsiTy and CardiovascUlaR DiseasE (NURTURE Center). “This study shows the great strides we have made in heart failure care, as well as opportunities for even more improvement.” 

Co-authors are Jamie Diamond, M.D., MPH; Iyanuoluwa Ayodele, MS; Karen E. Joynt-Maddox, M.D., MPH, FAHA; Robert W. Yeh, M.D., FAHA; Gmerice Hammond, M.D., MPH; Larry A. Allen, M.D., MHS, FAHA; Stephen J. Greene, M.D.; Karen Chiswell, PhD.; Adam D. DeVore, M.D., MHS; Clyde Yancy, M.D., FAHA; Rishi K. Wadhera, M.D., MPP, MPhil. Authors’ disclosures are listed in the manuscript. 

The study was supported by an American Heart Association Get With The Guidelines - HF Young Investigator Research Seed Grant. GWTG-HF is sponsored, in part, by Novartis, Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Novo Nordisk, Sanofi, AstraZeneca and Bayer. 

For more information: www.heart.org 

Related Content on New Technology and Ideas to Address Health Disparities:   

VIDEO: New Ideas in Addressing Cardiovascular Disease Disparities — Clyde Yancy, M.D   
VIDEO: How Smartphones May Revolutionize Healthcare in the Developing World —Interview with Jacques Kpodonu, M.D.   
VIDEO: Reducing Hypertension Among African-Americans — Interview with Kim Allan Williams, Sr., M.D.   
Multi-Ethnic Study of Atherosclerosis Sheds Light on Sleep Irregularity and Cardiovascular Disease 
STS Annual Meeting Session Rallies Proven Methods to Combat Racial, Gender Disparities in Heart and Lung Disease 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now